Introduction
Chronic hepatitis C (HCV) is a major public health problem estimated to affect approximately 3-4 million Americans or 1.8% of the general population in the United States. 1 In veterans treated within VA medical centers, the limited studies to date suggest that HCV prevalence rates may be 7-9%, or approximately fourfold the national average. 2 Epidemiological data suggest that those with the highest prevalence of HCV are African American, male, and 20-39 years of age. 3 Among individuals with HCV, 20-25% develop cirrhosis of the liver and/or hepatocellular carcinoma which result in an estimated death rate of 8000-10000 annually from hepatitis-associated chronic liver disease. 4 The most effective and generally available treatment for HCV is Rebetron, a combination therapy that includes alpha interferon (IFN) and ribavirin. 5 More recently, pegylated interferon alpha and ribavirin has been shown to have better sustained virologic response rates than Rebetron. 6 However, IFN causes significant neuropsychiatric side effects; 7 among the most prominent are symptoms of depression and cognitive impairment. 8, 9 These side effects negatively impact the patients' quality of life. 10, 11 Based on DSM-IV criteria, a depressive syndrome that occurs during IFN therapy is considered a substance-induced mood disorder. 12 Reported incidence rates of IFN-induced Major Depressive Disorder (MDD) range from 0-70% for all diseases, 13 and 0-44% for those with HCV infection.
14 Most studies have relied on patient self report rather than objective criterionbased instruments and questionnaires to assess IFNinduced depressive symptomatology. In those studies that used a specific instrument to assess depression, higher rates of MDD were found. 15 However, various depression rating scales were used. Other studies have found that while patients did not meet criteria for MDD, IFN therapy did cause symptoms of depression, resulting in high rates of subclinical psychiatric abnormalities. 8, 16 Because of this variability, the actual incidence of IFN-induced MDD remains largely unsubstantiated. Few studies have evaluated prospectively symptoms of depression in patients receiving IFN therapy.
Also unconfirmed is the usual time to development of MDD in patients on IFN therapy. In HCV patients undergoing IFN therapy, significant increases in depression have been reported anywhere from 12 weeks [17] [18] [19] to 6 months 11 after beginning IFN therapy. The majority of IFN therapy discontinuations that occur in HCV patients are related to the development of IFN-induced depression. 20 Due to the fact that neurotoxic symptoms usually resolve 2-3 weeks after IFN discontinuation, 21 many providers choose to decrease the dose or completely discontinue IFN therapy when psychiatric side effects occur. However, withdrawing a patient who is responding to IFN therapy denies them access to a potentially life-saving therapy. 22 To date, no controlled studies have explored the efficacy of SSRIs in treating IFN-induced MDD in a large sample of HCV patients receiving IFN therapy. Several case reports have suggested that antidepressants, 23 and SSRIs in particular, [24] [25] [26] are useful in ameliorating IFN-induced MDD. Also, in patients with malignant melanoma, prophylactic administration of SSRIs has been shown to prevent IFN-induced MDD, thus allowing patients to remain on therapeutic doses of IFN. 27, 28 Citalopram is a commonly used SSRI that is reported to have few metabolic side effects associated with liver disease and abnormalities. 29 In addition, citaprolam has been shown to be efficacious in ameliorating depressed mood, melancholia, sleep disturbance, anxiety, cognitive disturbance and psychomotor retardation, 29 which are common depressive symptoms associated with IFN therapy. Therefore, citaprolam is a reasonable candidate for treating IFN-induced MDD in patients with hepatitis C.
In summary, the vast majority of HCV studies have not used objective and validated measures of depressive symptomatology or criterion-based instruments to determine the MDD diagnosis, nor have they made these assessments prior to and during IFN therapy. Also, there is little information on the characteristics or treatment of IFN-induced MDD. Therefore the purpose of our study was to evaluate prospectively a cohort of HCV-infected patients prior to and after the implementation of IFN therapy in order to determine the following: (1) the incidence of IFN-induced MDD in HCV patients; (2) in those patients who developed MDD, the average length of time on IFN therapy until development of MDD; and (3) the efficacy of the SSRI citalopram in treating IFN-induced MDD.
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Methods
Participants
Ninety-two patients referred by the Baltimore VA Medical Center GI Clinic and the University of Maryland Hospital Hepatitis C Clinic were screened for the study. Of these, 53 were enrolled in the study. The remainder were ineligible as they had a current psychiatric or substance abuse history or did not wish to participate in the study. All patients had chronic HCV and were considered eligible for IFN therapy. The 39 patients included in this study had completed at least 2 months of IFN therapy or had developed IFNinduced MDD during the course of IFN therapy.
Eligibility
The protocol was explained to all patients who then signed the University of Maryland IRB-approved informed consent. Patients were eligible for the study if for 6 months prior to study entry, they had not had an active psychiatric illness, had not taken psychotropic medications, and had abstained from any psychoactive substance use.
Patients were administered the Structured Clinical Interview for DSM-IV Axis I Disorders, Version 2.0 (SCID-I/P) 30 to determine presence of psychiatric illness. In addition, present depressive symptoms were assessed by Beck Depression Inventory (BDI) prior to starting IFN therapy. 31 The BDI is a 21-item self-report inventory measuring characteristic attitudes and symptoms of depression, where a BDI Ͻ 10 is defined as asymptomatic. 32 Any patient who met the criteria for a current psychiatric illness or had significant symptoms of depression (defined as a BDI score Ͼ 15) was excluded from study participation.
Procedure
After the baseline BDI measurement, patients were prescribed and administered Rebetron combination therapy (IFN)-interferon alfa-2b injection of 3 million units/3 times per week and ribavirin capsules 600 mg day −1 for 6-12 months. BDIs were administered weekly over the course of IFN therapy. If at any point in the study, patients showed a BDI score of 18 or greater, they were reevaluated using the SCID-I/P to determine criteria for MDD. If a patient met criteria for MDD, he or she was started on antidepressant treatment.
The SSRI citalopram hydrobromide (Celexa) was used as the antidepressant. The starting dose of citalopram was 20 mg day −1 . Patients who showed no change in BDI score after one week of citalopram treatment had their dose increased by 20 mg per week to a maximum dose of 60 mg day −1 . Patients who were nonresponsive (BDI score reduction Ͻ50%) to a citalopram dose of 60 mg day −1 for 1 week were then given buproprion as an alternative antidepressant medication. Patients were considered to be in remission if their BDI score was Յ10.
Statistical analysis
Initial frequency comparisons were made between patients who developed MDD and those who did not, to examine the proportion of patients by gender, ethnic background, past history of substance abuse and past history of MDD. Yates corrected chi-square contingency tests ( 2 ) were used to determine whether the development of MDD during IFN treatment was associated with the aforementioned demographic variables.
Inferential statistics were calculated to examine differences between patients who developed MDD and those who did not. To make comparisons between the two groups, we accounted for baseline BDI score and highest BDI score. In MDD patients we measured time to IFN-induced MDD development (weeks from baseline BDI score/IFN therapy initiation to MDD development), escalation of depressive symptoms (weeks from last BDI Յ10 (asymptomatic) to MDD diagnosis), time to antidepressant efficacy (time to reduce high BDI score by 50% after SSRI treatment initiation) and time to remission (time to achieve BDI Յ10 after SSRI treatment initiation) using a previously reported technique. 33 For patients in the MDD group, additional comparisons were made between BDI score at baseline, highest BDI score and BDI score after 2 weeks on citalopram (or other antidepressant).
Results
Patient demographics and descriptive statistics are shown in Table 1 .
Of the total sample, 33.3% (13/39) met the criteria for MDD following initiation of IFN therapy. No significant differences were found between the MDD and non-MDD groups with respect to age. The proportion of patients with a past history of MDD ( 2 = 0.53, P = 0.48), or substance abuse ( 2 = 2.4, P = 0.12) was not greater in the MDD group. A significantly greater proportion of Caucasians were in the MDD group than in the non-MDD group ( 2 = 4.6, P Ͻ 0.05). At baseline, patients who later met criteria for IFNinduced MDD had BDI scores that were significantly higher than non-MDD patients (F = 8.7, P = 0.005). For the MDD group, the mean time from baseline to the development of a diagnosis of MDD was 12.1 weeks (median = 12; range 1-32 weeks, 6-22 weeks after removing low and high outliers), with a mean increase in BDI score of 20.0 ± 6.0 from baseline to MDD diagnosis. The patient distribution of weeks on IFN until MDD diagnosis develops is shown in Figure 1 .
In MDD patients, the escalation of depressive symptoms was measured as the time between the last BDI score Յ10 until a BDI score Ն18. The mean escalation time was 1.8 ± 2.4 weeks, with a mean increase in BDI score of 17.3 ± 5.2. Eight patients exhibited a rapid escalation of depressive symptoms that was Յ2 weeks with a mean increase in the BDI score of 17.3 ± 2.6.
Of the 13 MDD patients who developed depression, 85% (11/13) were responsive to antidepressant treatment. Nine of 11 patients responded to citalopram within the specified dose range of 20-60 mg day . One patient, who failed citalopram treatment, responded to buproprion at a dose of 300 mg day −1 . Of the two non-responders, one was lost to follow-up and a second had to discontinue IFN therapy because he developed IFN-induced MDD with psychotic features.
Patients responsive to antidepressants required an average of 5.4 (± 6.9) weeks on antidepressants until efficacy (defined as a decrease in BDI by 50%) was achieved, and an average of 9.0 (± 11.0) weeks until remission (defined as a BDI score Յ10) was achieved. The majority of these patients, 73% (8/11) were able to complete a full course of IFN therapy. One patient withdrew from IFN therapy for personal reasons even though his IFN-induced MDD was in remission and two withdrew from IFN therapy secondary to competing, unrelated medical conditions.
Discussion
In our prospective study of 39 patients with HCV who received IFN therapy, 33% (13/39) developed IFNinduced MDD. In those patients who developed MDD, depression usually developed between the 6th and 22nd week of IFN therapy (median = 12 weeks). The mean change in BDI score from baseline to highest BDI scores was 20 points for MDD patients (SD = 6; range 6-29) and 6.1 in non-MDD patients (SD = 4.6; range 0-17).
In contrast to previous published studies, a past history of MDD or substance abuse was not associated with an increased risk of IFN-induced MDD in our study. 19 However we did find that patients who later met criteria for IFN-induced MDD had baseline BDI scores that were significantly higher than non-MDD patients (6.9 ± 5.1 vs 2.8 ± 3.6; F = 8.7, P = 0.005) suggesting that patients with more symptoms of depression prior to IFN therapy may be at greater risk of developing IFN-induced MDD as compared with those who have few or no symptoms of depression. This finding supports studies of malignant melanoma patients, that showed depressive symptom scores 
MDD patients only
Total weeks on IFN to MDD diagnosis, weeks 12.1 ± 8.2 weeks (range 1-32 weeks) Escalation of depressive symptoms, weeks a 1.8 ± 2.4 weeks *P Ͻ 0.05. There were significantly more Caucasians in the depressed than non-depressed group. **P Ͻ 0.005. The depressed group had a significantly higher baseline BDI score than non-depressed group. a Escalation of depressive symptoms was calculated by taking mean number of days that elapsed between a BDI score Յ10 and the BDI score Ն18.
before IFN therapy were predictive of MDD development during IFN therapy. 28, 34 However, we wish to note that the mean baseline BDI score of patients who subsequently developed IFN-induced MDD was relatively low and did not indicate significant depressive symptomatology.
More than half of our patients who developed IFNinduced MDD became depressed during or after the 12th week of IFN therapy, suggesting that patients should be screened regularly for depression during the first 6 months of therapy. Furthermore, studies that screen or assess patients for depression only during the initial 12 weeks of therapy may grossly underestimate the actual incidence of IFN-induced depression.
Of the 13 patients who developed IFN-induced MDD, 85% (11/13) were responsive to antidepressant treatment. Most of these patients (9/11) responded to citalopram within the specified dose range of 20-60 mg day −1 (mean = 36.4 mg day
−1
). Our results met expectations anticipated from case reports that showed SSRIs are efficacious. 23 Furthermore, in those patients who responded, efficacy (defined as a decrease in BDI by 50%) was achieved, on average between 5-6 weeks and remission (defined as a BDI score Յ10) was achieved, on average in 9 weeks. The majority of our patients with IFN-induced MDD-62% (8/13)-completed a full course of IFN therapy. Only one patient developed Molecular Psychiatry IFN-induced MDD with psychotic symptoms that required discontinuation of IFN therapy.
Previous studies have reported that IFN-induced depression may include suicide ideation as well as suicide attempts necessitating early discontinuation of IFN therapy. 35 In our study, both MDD and non-MDD patients reported some symptoms of suicide ideation (n = 13). However, all of these patients rated themselves low on this item (suicidal thoughts without intent). This low score may have been due in part to frequent screening for depression using the BDI (weekly) and diagnosing and treating patients early during the course of MDD episode development.
We found that when depression developed in our patients it developed rapidly. In 62% (8/13) of our patients who developed IFN-induced MDD, BDI scores increased from 10 or less to 18 or more within 2 weeks. Our findings suggest that HCV patients undergoing IFN therapy should be screened ideally every 2 weeks. Such a recommendation could lead to early intervention by health care practitioners and prevention of neuropsychiatric side effects that would otherwise interrupt IFN therapy.
Limitations of our study include a relatively modest sample size. Access to a larger sample would help to clarify an optimal time interval for depression screening as part of the appropriate monitoring of HCV patients undergoing IFN therapy. However there are no prospective studies of HCV patients that have carefully examined the development and treatment of IFNinduced depression. Another limitation of our study is that our patients received combination therapy that includes alpha interferon and ribavirin. However, among the treated HCV population, it has been reported that the neuropsychiatric side is not exacerbated by the addition of ribavirin in (Rebetron) therapy, and ribavirin monotherapy has not been associated with a high incidence of neuropsychiatric side effects. 20, 22 A final limitation of our study was the open-label design, which may have resulted in an exaggerated response rate to antidepressant treatment.
In summary, our study suggests that IFN-induced MDD is common, occurring in 33% (13/39) of our patients. However, adjunctive antidepressant treatment, and citalopram in particular, is an effective treatment that can reverse IFN-induced depression and thus allow continuation of IFN, a potentially life-saving medication for patients with HCV. We did not find that HCV patients who develop IFN-induced MDD were more likely to have a past history of MDD or substance abuse. Therefore, we cautiously suggest that a past history of MDD or substance abuse should not automatically exclude HCV patients from IFN therapy.
The high frequency of IFN-induced MDD and the consideration that most HCV patients develop at least some symptoms of depression during IFN therapy raises the question of whether prophylactic antidepressant treatment may reduce the risk or prevent IFNinduced MDD and improve quality of life in HCV patients on IFN therapy. Studies in malignant melanoma patients suggest that prophylactic treatment with SSRIs prevents IFN-induced MDD and thus allows patients to remain on IFN therapy. 27, 28 Our study also supports the previously reported finding that higher baseline (pre-IFN therapy) depression scores may predict subsequent development of MDD. 28, 34 This suggests an alternative strategy, one that would target patients with higher depressive symptom scores for prophylactic treatment with antidepressants. However, we wish to make clear that in our study the mean baseline BDI scores for both MDD and non-MDD groups were Ͻ10 (6.9 and 2.8, respectively), suggesting few symptoms of depression. Currently, we cannot recommend that a patient with an increased baseline BDI score be treated prophylactically with antidepressants. Further research should be conducted before prophylactic antidepressant treatment is routinely prescribed for HCV patients prior to IFN therapy.
In conclusion, frequent screening for depression using established instruments offers the health care provider a tool that allows early intervention with antidepressant treatment for IFN-induced MDD. Ultimately this will reduce mortality as well as permit HCV patients to complete a full course of IFN therapy and possibly avoid the complications of advanced liver disease.
